Bionano Genomics, Inc. (BNGO) vs NextCure, Inc. (NXTC)

A side-by-side comparison of Bionano Genomics, Inc. and NextCure, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — BNGO vs NXTC

growth of $100 · dividends reinvested · last 7y
BNGO -99.9% (-65.2%/yr)NXTC -97.9% (-42.4%/yr)NXTC compounded faster over this window
Log scale — wide-divergence pair
001101001kStart $100202120232025$0$2
BNGO NXTC

BNGO vs NXTC: by the numbers

  • •NXTC is the larger company ($20M vs $17M market cap).
  • •Both run net losses; NXTC's is the smaller (0.00% vs -106.58% net margin).

Metrics side by side

Valuation

MetricBNGONXTC
P/S ratio0.55N/A
P/B ratio0.531.67

Profitability

MetricBNGONXTC
Gross margin21.95%0.00%
Operating margin-116.95%0.00%
Net margin-106.58%0.00%
ROE-101.76%-351.86%
ROIC-85.72%-259.91%

Growth (annualized)

MetricBNGONXTC
Revenue CAGR (5Y)17.97%N/A
Total return CAGR (5Y)-78.37%-44.29%

Frequently asked

How have BNGO and NXTC total returns compared?
Over the past 5 years, BNGO delivered -78.37% and NXTC delivered -44.29% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.